ReviewCurrent neuropharmacology2015
The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?
Review in Current neuropharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.The international journal of neuropsychopharmacology · 2017Pooled it
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.CNS drugs · 2026Review
- Anxiolytic and antidepressant effects of astaxanthin: behavioral and mechanistic insights in a rat model.Frontiers in pharmacology · 2026Article
- Modeling the genomic architecture of adiposity and anthropometrics across the lifespan.Nature communications · 2025Article
- Influence of Anticholinesterase Drugs on Activity and Properties of NaBulletin of experimental biology and medicine · 2024Article
- G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.Signal transduction and targeted therapy · 2023Review
- Normalization of impaired emotion inhibition in bipolar disorder mediated by cholinergic neurotransmission in the cingulate cortex.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Moderate Folic Acid Supplementation in Pregnant Mice Results in Altered Sex-Specific Gene Expression in Brain of Young Mice and Embryos.Nutrients · 2022Article
- NRM 2021 Abstract Booklet.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- New agents and perspectives in the pharmacological treatment of major depressive disorder.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Potential Role for Combined Subtype-Selective Targeting of MFrontiers in pharmacology · 2021Review
- Functional coupling of MEuropean archives of psychiatry and clinical neuroscience · 2020Article
- NaInternational journal of molecular sciences · 2020Article
- Na⁺, K⁺-ATPase Signaling and Bipolar Disorder.International journal of molecular sciences · 2018Review
- Sexually diergic hypothalamic-pituitary-adrenal axis responses to selective and non-selective muscarinic antagonists prior to cholinergic stimulation by physostigmine in rats.Brain research bulletin · 2018Article
- Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.Journal of neurochemistry · 2017Article
- Drugs Interfering with Muscarinic Acetylcholine Receptors and Their Effects on Place Navigation.Frontiers in psychiatry · 2017Review
- Current Trends in Identifying Rapidly Acting Treatments for Depression.Current behavioral neuroscience reports · 2016Article
- The Discriminative Stimulus Properties of Drugs Used to Treat Depression and Anxiety.Current topics in behavioral neurosciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The central cholinergic system has been implicated in the pathophysiology of mood disorders. An imbalance in central cholinergic neurotransmitter activity has been proposed to contribute to the manic and depressive episodes typical of these disorders. Neuropharmacological studies into the effects of cholinergic agonists and antagonists on mood state have provided considerable support for this hypothesis. Furthermore, recent clinical studies have shown that the pan-CHRM antagonist, scopolamine, produces rapid-acting antidepressant effects in individuals with either major depressive disorder (MDD) or bipolar disorder (BPD), such as bipolar depression, contrasting the delayed therapeutic response of conventional mood stabilisers and antidepressants. This review presents recent data from neuroimaging, post-mortem and genetic studies supporting the involvement of muscarinic cholinergic receptors (CHRMs), particularly CHRM2, in the pathophysiology of MDD and BPD. Thus, novel drugs that selectively target CHRMs with negligible effects in the peripheral nervous system might produce more rapid and robust clinical improvement in patients with BPD and MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.